PALYNZIQ
Total Payments
$3.6M
Transactions
398
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.6M | 398 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.6M | 398 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 3 substudy enrolling approximately 100 subjects aged 18 to 70 years old with PKU who are concurrently participating in the 165-302 study | BioMarin Pharmaceutical Inc. | $2.5M | 0 |
| BMN 165-501 | BioMarin Pharmaceutical Inc. | $402,630 | 0 |
| BMN 165-508 | BioMarin Pharmaceutical Inc. | $222,579 | 0 |
| BMN 165-503 | BioMarin Pharmaceutical Inc. | $173,268 | 0 |
| A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondroplasia | BioMarin Pharmaceutical Inc. | $64,612 | 0 |
| A Preliminary Study of the Neurological and Neuropsychological Effects of Palynziq-Related Changes in Phenylalanine in Individuals with Phenylketonuria (PKU) | BioMarin Pharmaceutical Inc. | $55,000 | 0 |
| An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | BioMarin Pharmaceutical Inc. | $54,556 | 0 |
| BMN 111-902 | BioMarin Pharmaceutical Inc. | $44,068 | 0 |
| PalynziqTM and PKU: Treatment Impacts on Diet Quality, Neurological health, Nutritional Status, and the Metabolome | BioMarin Pharmaceutical Inc. | $31,676 | 0 |
| BMN165-306 | BioMarin Pharmaceutical Inc. | $25,937 | 0 |
| Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects with Phenylketonuria and Plasma Phe Levels > 600 umol/L | BioMarin Pharmaceutical Inc. | $22,147 | 0 |
| Palynziq and PKU : Treatment Impacts on Diet Quality, Neurological Health, Nutritional Status and the Metabolome | BioMarin Pharmaceutical Inc. | $15,416 | 0 |
| Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients | BioMarin Pharmaceutical Inc. | $11,032 | 0 |
| Cerliponase alfa Observational Study (US) | BioMarin Pharmaceutical Inc. | $1,600 | 0 |
Top Doctors Receiving Payments for PALYNZIQ
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Northbrook, IL | $3.6M | 398 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.6M
- Total Doctors 0
- Transactions 398
About PALYNZIQ
PALYNZIQ is a drug associated with $3.6M in payments to 0 healthcare providers, recorded across 398 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2024 to 2024. In 2024, $3.6M was paid across 398 transactions to 0 doctors.
The most common payment nature for PALYNZIQ is "Unspecified" ($3.6M, 100.0% of total).
PALYNZIQ is associated with 14 research studies, including "Phase 3 substudy enrolling approximately 100 subjects aged 18 to 70 years old with PKU who are concurrently participating in the 165-302 study" ($2.5M).